JP2010500393A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010500393A5 JP2010500393A5 JP2009524178A JP2009524178A JP2010500393A5 JP 2010500393 A5 JP2010500393 A5 JP 2010500393A5 JP 2009524178 A JP2009524178 A JP 2009524178A JP 2009524178 A JP2009524178 A JP 2009524178A JP 2010500393 A5 JP2010500393 A5 JP 2010500393A5
- Authority
- JP
- Japan
- Prior art keywords
- layer
- pharmaceutically acceptable
- controlled release
- optional
- polymers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000013270 controlled release Methods 0.000 claims description 47
- PPRRDFIXUUSXRA-UHFFFAOYSA-N flibanserin Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCN3C(NC4=CC=CC=C43)=O)CC2)=C1 PPRRDFIXUUSXRA-UHFFFAOYSA-N 0.000 claims description 37
- 229960002053 flibanserin Drugs 0.000 claims description 37
- 229920003176 water-insoluble polymer Polymers 0.000 claims description 22
- 229920000642 polymer Polymers 0.000 claims description 21
- 239000011162 core material Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 125000000129 anionic group Chemical group 0.000 claims description 16
- 230000004888 barrier function Effects 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000004014 plasticizer Substances 0.000 claims description 7
- 239000000049 pigment Substances 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 5
- 239000006185 dispersion Substances 0.000 claims description 4
- 125000003010 ionic group Chemical group 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000002270 dispersing agent Substances 0.000 claims description 3
- 235000008429 bread Nutrition 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000001125 extrusion Methods 0.000 claims description 2
- 238000005563 spheronization Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229920003169 water-soluble polymer Polymers 0.000 claims 2
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 230000016571 aggressive behavior Effects 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 238000012377 drug delivery Methods 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000022821 personality disease Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 238000007493 shaping process Methods 0.000 claims 1
- 230000007958 sleep Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 239000010410 layer Substances 0.000 description 75
- 239000011248 coating agent Substances 0.000 description 28
- 238000000576 coating method Methods 0.000 description 28
- 239000003002 pH adjusting agent Substances 0.000 description 23
- 238000004090 dissolution Methods 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- 230000036470 plasma concentration Effects 0.000 description 8
- 230000009885 systemic effect Effects 0.000 description 6
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- -1 oral administration Chemical compound 0.000 description 4
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229920001800 Shellac Polymers 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
- 239000004208 shellac Substances 0.000 description 2
- 229940113147 shellac Drugs 0.000 description 2
- 235000013874 shellac Nutrition 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229920005601 base polymer Polymers 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000004815 dispersion polymer Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229920000847 nonoxynol Polymers 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06118896.7 | 2006-08-14 | ||
| EP06118896 | 2006-08-14 | ||
| EP06017754 | 2006-08-25 | ||
| EP06017754.0 | 2006-08-25 | ||
| PCT/EP2007/058301 WO2008019996A2 (en) | 2006-08-14 | 2007-08-10 | Formulations of flibanserin and method for manufacturing the same |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013140892A Division JP2013189481A (ja) | 2006-08-14 | 2013-07-04 | フリバンセリンの製剤及びその製造方法 |
| JP2015125682A Division JP2015164965A (ja) | 2006-08-14 | 2015-06-23 | フリバンセリンの製剤及びその製造方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010500393A JP2010500393A (ja) | 2010-01-07 |
| JP2010500393A5 true JP2010500393A5 (enExample) | 2015-08-06 |
| JP5793828B2 JP5793828B2 (ja) | 2015-10-14 |
Family
ID=38573304
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009524178A Active JP5793828B2 (ja) | 2006-08-14 | 2007-08-10 | フリバンセリンの製剤及びその製造方法 |
| JP2013140892A Pending JP2013189481A (ja) | 2006-08-14 | 2013-07-04 | フリバンセリンの製剤及びその製造方法 |
| JP2015125682A Pending JP2015164965A (ja) | 2006-08-14 | 2015-06-23 | フリバンセリンの製剤及びその製造方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013140892A Pending JP2013189481A (ja) | 2006-08-14 | 2013-07-04 | フリバンセリンの製剤及びその製造方法 |
| JP2015125682A Pending JP2015164965A (ja) | 2006-08-14 | 2015-06-23 | フリバンセリンの製剤及びその製造方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8658207B2 (enExample) |
| EP (1) | EP2054041A2 (enExample) |
| JP (3) | JP5793828B2 (enExample) |
| KR (1) | KR20090042967A (enExample) |
| AR (1) | AR062320A1 (enExample) |
| AU (1) | AU2007286288A1 (enExample) |
| BR (1) | BRPI0716439B8 (enExample) |
| CA (1) | CA2660476C (enExample) |
| CL (1) | CL2007002356A1 (enExample) |
| CO (1) | CO6150127A2 (enExample) |
| EA (1) | EA200900264A1 (enExample) |
| IL (1) | IL196979A (enExample) |
| MX (1) | MX2009001551A (enExample) |
| NO (1) | NO20090081L (enExample) |
| PE (1) | PE20080423A1 (enExample) |
| TW (1) | TW200817007A (enExample) |
| UY (1) | UY30537A1 (enExample) |
| WO (1) | WO2008019996A2 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
| US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
| US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
| EP1740181A1 (en) * | 2004-04-22 | 2007-01-10 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for the treatment of sexual disorders ii |
| US20060025420A1 (en) * | 2004-07-30 | 2006-02-02 | Boehringer Ingelheimn International GmbH | Pharmaceutical compositions for the treatment of female sexual disorders |
| EP1789048A1 (en) * | 2004-09-03 | 2007-05-30 | Boehringer Ingelheim International GmbH | Method for the treatment of attention deficit hyperactivity disorder |
| WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
| CA2599721A1 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of depression |
| CA2608249A1 (en) * | 2005-05-06 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Method for the treatment of drug abuse with flibanserin |
| JP2008540673A (ja) * | 2005-05-19 | 2008-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 薬剤誘発性性機能不全の治療方法 |
| CA2608713A1 (en) * | 2005-05-19 | 2006-11-23 | Boehringer Ingelheim International Gmbh | Method for the treatment of sexual dysfunctions due to medical conditions |
| EP1912650B8 (en) * | 2005-08-03 | 2017-10-18 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
| EP1945214A1 (en) * | 2005-10-29 | 2008-07-23 | Boehringer Ingelheim International GmbH | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
| US20070123540A1 (en) * | 2005-10-29 | 2007-05-31 | Angelo Ceci | Sexual desire enhancing medicaments comprising benzimidazolone derivatives |
| US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
| PT2021006E (pt) * | 2006-05-09 | 2015-11-12 | Sprout Pharmaceuticals Inc | Uso de flibanserina para o tratamento de distúrbios de desejo sexual pós-menopausa |
| JP2009541443A (ja) | 2006-06-30 | 2009-11-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 尿失禁及び関連疾患の治療のためのフリバンセリン |
| US20090318469A1 (en) * | 2006-07-14 | 2009-12-24 | Boehringer Ingelheim International Gmbh | Use of Flibanserin for the Treatment of Sexual Disorders in Females |
| KR20090042967A (ko) | 2006-08-14 | 2009-05-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 플리반세린 제형 및 이의 제조방법 |
| CL2007002214A1 (es) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
| CN104721168A (zh) | 2006-08-25 | 2015-06-24 | 贝林格尔·英格海姆国际有限公司 | 控制释放系统及其制造方法 |
| WO2008074795A1 (en) | 2006-12-20 | 2008-06-26 | Boehringer Ingelheim International Gmbh | Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity |
| WO2008090742A1 (ja) * | 2007-01-23 | 2008-07-31 | National University Corporation Hokkaido University | 眼疾患モデル用非ヒト動物 |
| CL2008002693A1 (es) | 2007-09-12 | 2009-10-16 | Boehringer Ingelheim Int | Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad |
| DE102008004893A1 (de) * | 2008-01-17 | 2009-07-23 | Add Technologies Ltd. | Trägerpellets, Verfahren zu deren Herstellung und deren Verwendung |
| EP2090297A1 (en) * | 2008-02-13 | 2009-08-19 | Boehringer Ingelheim International GmbH | Formulations of flibanserin |
| CA2686480A1 (en) * | 2008-12-15 | 2010-06-15 | Boehringer Ingelheim International Gmbh | New salts |
| EP3485878A1 (en) * | 2010-09-01 | 2019-05-22 | Arena Pharmaceuticals, Inc. | Modified-release dosage forms of 5-ht2c agonists useful for weight management |
| CN103648487B (zh) * | 2011-05-13 | 2019-04-19 | Eb Ip希博里塔布斯有限责任公司 | 药物递送系统 |
| KR101446066B1 (ko) | 2012-12-14 | 2014-10-01 | 박재돈 | 구안파신 함유 경구용 서방성 캡슐제 조성물 |
| US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US12365689B2 (en) | 2015-10-16 | 2025-07-22 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11780848B2 (en) | 2015-10-16 | 2023-10-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
| US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| CA3251507A1 (en) | 2015-10-16 | 2025-05-21 | Abbvie Inc | Use of a solid dosage form comprising (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide for treating rheumatoid arthritis |
| US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| CN109517792B (zh) * | 2018-12-04 | 2021-03-16 | 中南大学湘雅三医院 | 一种新旧红细胞的分离介质及其制备方法与应用 |
Family Cites Families (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US543156A (en) * | 1895-07-23 | Automatic railroad-switch | ||
| US3096248A (en) | 1959-04-06 | 1963-07-02 | Rexall Drug & Chemical Company | Method of making an encapsulated tablet |
| US3406178A (en) * | 1964-02-04 | 1968-10-15 | Monsanto Chem Australia Ltd | Preparation of 2-substituted benzimidazoles |
| US3362956A (en) * | 1965-08-19 | 1968-01-09 | Sterling Drug Inc | 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines |
| US4200641A (en) * | 1976-12-21 | 1980-04-29 | Janssen Pharmaceutica, N.V. | 1-[(Heterocyclyl)-alkyl]-4-diarylmethoxy piperidine derivatives |
| IL57569A0 (en) | 1978-06-20 | 1979-10-31 | Synthelabo | Phenylpiperazine derivative,their preparation and pharmaceutical compositions containing them |
| DE3000979A1 (de) | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
| IT1176613B (it) * | 1984-08-14 | 1987-08-18 | Ravizza Spa | Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione |
| IE58370B1 (en) | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
| GB8607294D0 (en) * | 1985-04-17 | 1986-04-30 | Ici America Inc | Heterocyclic amide derivatives |
| NL8601494A (nl) | 1985-06-22 | 1987-01-16 | Sandoz Ag | Thiazolen, hun bereiding en farmaceutische preparaten die ze bevatten. |
| DE3620643A1 (de) | 1985-06-22 | 1987-01-22 | Sandoz Ag | Thiazole, ihre herstellung und verwendung |
| GB8601160D0 (en) * | 1986-01-17 | 1986-02-19 | Fujisawa Pharmaceutical Co | Heterocyclic compounds |
| US5036088A (en) * | 1986-06-09 | 1991-07-30 | Pfizer Inc. | Antiallergy and antiinflammatory agents, compositions and use |
| JPH0784462B2 (ja) * | 1986-07-25 | 1995-09-13 | 日清製粉株式会社 | ベンゾイミダゾ−ル誘導体 |
| US4968508A (en) * | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
| US4792452A (en) * | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| GB8830312D0 (en) | 1988-12-28 | 1989-02-22 | Lundbeck & Co As H | Heterocyclic compounds |
| US4954503A (en) * | 1989-09-11 | 1990-09-04 | Hoechst-Roussel Pharmaceuticals, Inc. | 3-(1-substituted-4-piperazinyl)-1H-indazoles |
| DE69129839T2 (de) | 1990-08-24 | 1999-02-11 | Shin-Etsu Chemical Co., Ltd., Tokio/Tokyo | Beschichtungsbase für einen pharmazeutischen film und verfahren zur herstellung derselben |
| NZ241613A (en) * | 1991-02-27 | 1993-06-25 | Janssen Pharmaceutica Nv | Highlighting intagliations in tablets |
| SE9100860D0 (sv) | 1991-03-22 | 1991-03-22 | Kabi Pharmacia Ab | New use |
| FR2675800A1 (fr) | 1991-04-26 | 1992-10-30 | Rhone Poulenc Rorer Sa | Derives heterocycliques antiserotonines leur preparation et les medicaments les contenant. |
| IT1251144B (it) | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US5225417A (en) * | 1992-01-21 | 1993-07-06 | G. D. Searle & Co. | Opioid agonist compounds |
| US5492907A (en) | 1992-12-09 | 1996-02-20 | The United States Of America As Represented By The Department Of Health & Human Services | Antipsychotic composition and method of treatment |
| FR2707294B1 (fr) * | 1993-07-06 | 1995-09-29 | Pf Medicament | Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine. |
| GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| ES2163506T3 (es) | 1994-06-14 | 2002-02-01 | Pfizer | Derivados de bencimidazolona con actividad dopaminergica central. |
| PT777477E (pt) | 1994-08-23 | 2003-03-31 | Smithkline Beecham Plc | Formulacoes farmaceuticas melhoradas contendo ibuprofen e codeina |
| ES2204932T3 (es) | 1994-09-12 | 2004-05-01 | Eli Lilly And Company Limited | Moduladores serotonergicos. |
| FR2727682A1 (fr) * | 1994-12-02 | 1996-06-07 | Pf Medicament | Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament |
| US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| US5883094A (en) * | 1995-04-24 | 1999-03-16 | Pfizer Inc. | Benzimidazolone derivatives with central dopaminergic activity |
| US5854290A (en) * | 1995-09-21 | 1998-12-29 | Amy F. T. Arnsten | Use of guanfacine in the treatment of behavioral disorders |
| US6083947A (en) * | 1996-01-29 | 2000-07-04 | The Regents Of The University Of California | Method for treating sexual dysfunctions |
| GB9613423D0 (en) | 1996-06-26 | 1996-08-28 | Lilly Industries Ltd | Pharmaceutical compounds |
| US5916916A (en) | 1996-10-10 | 1999-06-29 | Eli Lilly And Company | 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods |
| ATE271379T1 (de) | 1996-11-06 | 2004-08-15 | Wockhardt Europ Ltd | System zur verzögerten freisetzung säurelabiler substanzen |
| JP2001504851A (ja) | 1996-12-02 | 2001-04-10 | メルク シヤープ エンド ドーム リミテツド | 性的機能不全の治療のためのｎｋ−１受容体拮抗薬の使用 |
| US5859246A (en) | 1997-01-30 | 1999-01-12 | Neurogen Corporation | 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands |
| GB9706089D0 (en) | 1997-03-24 | 1997-05-14 | Scherer Ltd R P | Pharmaceutical composition |
| US20040023948A1 (en) * | 1997-03-24 | 2004-02-05 | Green Richard David | Fast-dispersing dosage form containing 5-HT1 agonists |
| BR9810027A (pt) * | 1997-06-11 | 2000-09-12 | Procter & Gamble | Comprimido revestido por pelìcula para melhorada segurança do trato gastrintestinal superior |
| ATE241341T1 (de) | 1997-09-10 | 2003-06-15 | Takeda Chemical Industries Ltd | Stabilisierte pharmazeutische zusammensetzung |
| SE9703375D0 (sv) | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
| CH692199A8 (fr) | 1997-10-09 | 2002-06-14 | Cermol S.A. | Composes pyridiques et compositions pharmaceutique |
| JP3724157B2 (ja) | 1997-10-30 | 2005-12-07 | コニカミノルタホールディングス株式会社 | 映像観察装置 |
| FR2775188B1 (fr) * | 1998-02-23 | 2001-03-09 | Lipha | Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption |
| WO1999059584A1 (en) | 1998-05-20 | 1999-11-25 | Schering Corporation | Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction |
| US20020151543A1 (en) | 1998-05-28 | 2002-10-17 | Sepracor Inc. | Compositions and methods employing R (-) fluoxetine and other active ingredients |
| US6068846A (en) | 1998-08-05 | 2000-05-30 | Melaleuca, Incorporated | Methods and materials for treating depression and mood disorder |
| EP0982030A3 (en) * | 1998-08-17 | 2000-05-10 | Pfizer Products Inc. | 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands |
| UA67802C2 (uk) | 1998-10-23 | 2004-07-15 | Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. | Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції |
| WO2000028993A1 (en) | 1998-11-19 | 2000-05-25 | Nortran Pharmaceuticals, Inc. | Serotonin ligands as pro-erectile compounds |
| US6680071B1 (en) * | 1999-03-03 | 2004-01-20 | R. P. Scherer Technologies, Inc. | Opioid agonist in a fast dispersing dosage form |
| WO2000063189A1 (en) | 1999-04-16 | 2000-10-26 | Novo Nordisk A/S | Crystalline r- guanidines, arginine or (l) -arginine (2s) -2- ethoxy -3-{4- [2-(10h -phenoxazin -10-yl)ethoxy]phenyl}propanoate |
| CN1461216A (zh) | 1999-04-28 | 2003-12-10 | 呼吸器有限公司 | 用作治疗有关支气管收缩的机能障碍的药物的化合物 |
| IT1312310B1 (it) | 1999-05-07 | 2002-04-15 | Recordati Ind Chimica E Farma | Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale |
| US6579968B1 (en) | 1999-06-29 | 2003-06-17 | Palatin Technologies, Inc. | Compositions and methods for treatment of sexual dysfunction |
| US6346548B1 (en) | 1999-08-16 | 2002-02-12 | Cephalon, Inc. | Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
| IT1313625B1 (it) * | 1999-09-22 | 2002-09-09 | Boehringer Ingelheim Italia | Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina. |
| CN1396829A (zh) | 2000-02-24 | 2003-02-12 | 法玛西雅厄普约翰美国公司 | 新的药物联合形式 |
| AU2001260548A1 (en) | 2000-06-28 | 2002-01-08 | Pfizer Products Inc. | Melanocortin receptor ligands |
| US6586435B2 (en) * | 2000-09-19 | 2003-07-01 | Boehringer Ingelheim Pharma Kg | Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors |
| MXPA03002329A (es) | 2000-09-19 | 2003-10-15 | Boehringer Ingelheim Pharma | Nuevos derivados de bencimidazolona que muestran afinidad por los receptores de serotonina y dopamina. |
| US6521623B1 (en) * | 2000-09-19 | 2003-02-18 | Boehringer Ingelheim Pharma Kg | N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors |
| AU2002226895B2 (en) | 2000-11-22 | 2006-10-12 | Abbott Laboratories | Selective dopamine D4 receptor agonists for treating sexual dysfunction |
| GB0105893D0 (en) | 2001-03-09 | 2001-04-25 | Pfizer Ltd | Pharmaceutically active compounds |
| KR100564466B1 (ko) | 2001-03-28 | 2006-03-29 | 화이자 인코포레이티드 | Ｆｓａｄ에 대한 ｎｅｐ 억제제로서의ｎ-펜프로필사이클로펜틸-치환된 글루타르아미드 유도체 |
| DE60121301T2 (de) * | 2001-05-11 | 2007-07-19 | Beck, Jürgen, Dr. | Flibanserin zur Behandlung extrapyramidaler Bewegungsstörungen |
| US6627646B2 (en) | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
| US7115628B2 (en) | 2001-07-18 | 2006-10-03 | Merck & Co., Inc. | Bridged piperidine derivatives as melanocortin receptor agonists |
| DE60231070D1 (de) | 2001-07-30 | 2009-03-19 | Spectrum Pharmaceuticals Inc | Arylpiperazin gebundene Purinderivate |
| US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
| AU2002331361B2 (en) | 2001-08-02 | 2008-06-05 | Sprout Pharmaceuticals, Inc. | Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments |
| DE10138273A1 (de) | 2001-08-10 | 2003-02-27 | Boehringer Ingelheim Pharma | Arzneimittel mit neuroprotektiver Wirkung |
| US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
| HUP0202719A3 (en) | 2001-08-21 | 2006-01-30 | Pfizer Prod Inc | Pharmaceutical compositions for the treatment of female sexual dysfunctions |
| DE10149674A1 (de) * | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung |
| UA78974C2 (en) * | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| DE10209982A1 (de) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma | Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe |
| US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
| RS51718B (sr) | 2002-05-22 | 2011-10-31 | Boehringer Ingelheim Pharma Gmbh. & Co.Kg. | Nove farmaceutske kompozicije koje sadrže flibanserin polimorf a |
| US20040116532A1 (en) * | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
| GB0225908D0 (en) | 2002-11-06 | 2002-12-11 | Pfizer Ltd | Treatment of female sexual dysfunction |
| US20040132697A1 (en) | 2002-11-06 | 2004-07-08 | Pfizer Inc. | Treatment of female sexual dysfunction |
| US20040147581A1 (en) | 2002-11-18 | 2004-07-29 | Pharmacia Corporation | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy |
| WO2004063864A2 (en) * | 2003-01-06 | 2004-07-29 | Laura Berman | Method and system for computerized sexual function assessment of female users |
| WO2004069339A1 (en) | 2003-01-29 | 2004-08-19 | Psychogenics Inc. | Treatment for attention-deficit hyperactivity disorder |
| US20050037983A1 (en) | 2003-03-11 | 2005-02-17 | Timothy Dinan | Compositions and methods for the treatment of depression and other affective disorders |
| BRPI0411985A (pt) | 2003-07-16 | 2006-08-29 | Pfizer | tratamento da disfunção sexual |
| US20050065158A1 (en) * | 2003-07-16 | 2005-03-24 | Pfizer Inc. | Treatment of sexual dysfunction |
| WO2005044238A1 (en) | 2003-11-07 | 2005-05-19 | Ranbaxy Laboratories Limited | Modified release solid dosage form of amphetamine salts |
| EP1740181A1 (en) * | 2004-04-22 | 2007-01-10 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for the treatment of sexual disorders ii |
| US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
| US20060014757A1 (en) * | 2004-07-14 | 2006-01-19 | Boehringer Ingelheim Pharmaceuticals | Method for the treatment of anorexia nervosa |
| US20060025420A1 (en) | 2004-07-30 | 2006-02-02 | Boehringer Ingelheimn International GmbH | Pharmaceutical compositions for the treatment of female sexual disorders |
| EP1789048A1 (en) | 2004-09-03 | 2007-05-30 | Boehringer Ingelheim International GmbH | Method for the treatment of attention deficit hyperactivity disorder |
| JP2008531714A (ja) * | 2005-03-04 | 2008-08-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 不安障害の治療用及び／又は予防用の医薬組成物 |
| WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
| CA2599721A1 (en) | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of depression |
| CA2608249A1 (en) * | 2005-05-06 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Method for the treatment of drug abuse with flibanserin |
| US20060258640A1 (en) * | 2005-05-13 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Use of Flibanserin in the treatment of chronic pain |
| CA2608713A1 (en) * | 2005-05-19 | 2006-11-23 | Boehringer Ingelheim International Gmbh | Method for the treatment of sexual dysfunctions due to medical conditions |
| JP2008540673A (ja) * | 2005-05-19 | 2008-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 薬剤誘発性性機能不全の治療方法 |
| EP1912650B8 (en) | 2005-08-03 | 2017-10-18 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
| HU227490B1 (en) | 2005-08-26 | 2011-07-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Sustained release pharmaceutical preparation containing carvedilol |
| EP1945214A1 (en) | 2005-10-29 | 2008-07-23 | Boehringer Ingelheim International GmbH | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
| US20070123540A1 (en) * | 2005-10-29 | 2007-05-31 | Angelo Ceci | Sexual desire enhancing medicaments comprising benzimidazolone derivatives |
| US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
| KR20140088230A (ko) | 2006-01-27 | 2014-07-09 | 앱탈리스 파마테크, 인코포레이티드 | 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템 |
| CA2641917A1 (en) | 2006-02-18 | 2007-08-23 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin |
| EP1988897A1 (en) | 2006-02-20 | 2008-11-12 | Boehringer Ingelheim International GmbH | Benzimidazolone derivatives for the treatment of urinary incontinence |
| CA2642368A1 (en) | 2006-02-28 | 2007-09-07 | Boehringer Ingelheim International Gmbh | Treatment of prevention of valvular heart disease with flibanserin |
| PT2021006E (pt) | 2006-05-09 | 2015-11-12 | Sprout Pharmaceuticals Inc | Uso de flibanserina para o tratamento de distúrbios de desejo sexual pós-menopausa |
| JP2009541443A (ja) | 2006-06-30 | 2009-11-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 尿失禁及び関連疾患の治療のためのフリバンセリン |
| US20090318469A1 (en) | 2006-07-14 | 2009-12-24 | Boehringer Ingelheim International Gmbh | Use of Flibanserin for the Treatment of Sexual Disorders in Females |
| WO2008006839A2 (en) | 2006-07-14 | 2008-01-17 | Boehringer Ingelheim International Gmbh | Combinations of flibanserin with caffeine, process for their preparation and use thereof as medicaments |
| CA2671200A1 (en) * | 2006-07-21 | 2008-01-24 | Lab International Srl | Hydrophilic abuse deterrent delivery system |
| KR20090042967A (ko) | 2006-08-14 | 2009-05-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 플리반세린 제형 및 이의 제조방법 |
| CL2007002214A1 (es) * | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
| CN104721168A (zh) | 2006-08-25 | 2015-06-24 | 贝林格尔·英格海姆国际有限公司 | 控制释放系统及其制造方法 |
| JP2010522714A (ja) | 2007-03-28 | 2010-07-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規な医薬組成物 |
-
2007
- 2007-08-10 KR KR1020097005345A patent/KR20090042967A/ko not_active Withdrawn
- 2007-08-10 WO PCT/EP2007/058301 patent/WO2008019996A2/en not_active Ceased
- 2007-08-10 AR ARP070103544A patent/AR062320A1/es unknown
- 2007-08-10 MX MX2009001551A patent/MX2009001551A/es active IP Right Grant
- 2007-08-10 BR BRPI0716439A patent/BRPI0716439B8/pt active IP Right Grant
- 2007-08-10 JP JP2009524178A patent/JP5793828B2/ja active Active
- 2007-08-10 EP EP07788357A patent/EP2054041A2/en not_active Ceased
- 2007-08-10 AU AU2007286288A patent/AU2007286288A1/en not_active Abandoned
- 2007-08-10 CA CA2660476A patent/CA2660476C/en active Active
- 2007-08-10 EA EA200900264A patent/EA200900264A1/ru unknown
- 2007-08-13 UY UY30537A patent/UY30537A1/es not_active Application Discontinuation
- 2007-08-13 US US11/837,959 patent/US8658207B2/en active Active
- 2007-08-13 PE PE2007001081A patent/PE20080423A1/es not_active Application Discontinuation
- 2007-08-13 TW TW096129887A patent/TW200817007A/zh unknown
- 2007-08-13 CL CL200702356A patent/CL2007002356A1/es unknown
-
2009
- 2009-01-07 NO NO20090081A patent/NO20090081L/no not_active Application Discontinuation
- 2009-02-09 IL IL196979A patent/IL196979A/en active IP Right Grant
- 2009-02-13 CO CO09014464A patent/CO6150127A2/es unknown
-
2013
- 2013-07-04 JP JP2013140892A patent/JP2013189481A/ja active Pending
-
2015
- 2015-06-23 JP JP2015125682A patent/JP2015164965A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010500393A5 (enExample) | ||
| JP5793828B2 (ja) | フリバンセリンの製剤及びその製造方法 | |
| TWI267385B (en) | Controlled release bead, pharmaceutical formulation comprising the same and production thereof | |
| JP4971159B2 (ja) | プラミペキソール又はその薬学的に許容しうる塩を含有する徐放性ペレット製剤、その製法及び使用 | |
| JP3015105B2 (ja) | 粉末被覆経口投与剤形 | |
| JP4732696B2 (ja) | 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤 | |
| JP5636364B2 (ja) | 徐放性骨格筋弛緩薬剤形の調製 | |
| EP1178781A1 (de) | Mehrschichtige arzneiform für die colonfreigabe | |
| JP2017514903A (ja) | 徐放性懸濁組成物 | |
| JP2005526738A (ja) | 低溶解度の薬物を経口投与するための投与剤形 | |
| RU2372893C2 (ru) | Содержащий фармацевтический агент состав с покрытием | |
| EP2217210A2 (de) | Retardtabletten mit hydromorphon | |
| CA2645940A1 (en) | Controlled release formulation of tolterodine | |
| US10517829B2 (en) | Extended release pharmaceutical compositions | |
| US20090192228A1 (en) | Controlled-Release Tolterodine Compositions and Methods | |
| JP2009510027A (ja) | ベンラファキシン塩酸塩の制御放出性の医薬組成物、及びその調製方法 | |
| CN115737597A (zh) | 一种口服的肠溶速释药物组合物、制备方法及其应用 | |
| CN101933913A (zh) | 一种盐酸右哌甲酯双释放制剂及其制备方法 | |
| JP7374992B2 (ja) | 有効成分を遠位結腸で遅延放出する多層構造ペレット剤 | |
| JP6787928B2 (ja) | リバスチグミン含有徐放出医薬組成物 | |
| EP3892263A1 (en) | Oral dosage form | |
| WO2013158638A1 (en) | Stable dosage forms of skeletal muscle relaxants with extended release coating | |
| EP3184101A1 (en) | Levodopa and carbidopa modified release composition | |
| CN101530387B (zh) | 口服迟释药物制剂 | |
| DE102011075354A1 (de) | Arzneiform zur gezielten Freigabe von Wirkstoffen |